Identification

Name
Methylene blue
Accession Number
DB09241
Type
Small Molecule
Groups
Approved, Investigational
Description

Methylene blue has been found to have many uses in medicine.

It has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. It has been used as well for treatment of methemoglobinemia and other conditions. Methylene blue could also be used as urinary tract antiseptic.

Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease.

Structure
Thumb
Synonyms
  • Basic Blue 9
  • C.I. basic blue 9
  • Lowacryl blue 9
  • Methylene blue
  • Methylene blue anhydrous
  • methylenium ceruleum
  • Methylthioninium chloride
External IDs
C.I. 52015 / CI 52015 / CI-52015 / NSC-617593 / TRX-0014 / TRX0014
Product Ingredients
IngredientUNIICASInChI Key
Methylene blue trihydrateT42P99266K7220-79-3XQAXGZLFSSPBMK-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methylene Blue Inj 1%Liquid10 mgIntramuscular; IntravenousAllen & Hanburys A Glaxo Canada Ltd. Co.1979-12-311996-09-10Canada
Methylene Blue Inj 1% USPLiquid1 %IntravenousDavid Bull Laboratories (Pty) Ltd.1991-12-311999-08-10Canada
Methylene Blue Inj 10mg/ml USPLiquid10 mgIntravenousGlaxo Canada Inc1979-12-311996-09-10Canada
Methylene Blue InjectionSolution10 mgIntravenousTeligent Ou2016-02-19Not applicableCanada
Methylene Blue Injection USPLiquid10 mgIntravenousOmega Laboratories Ltd2001-03-11Not applicableCanada
Methylene Blue Injection USPSolution10 mgParenteralSandoz Canada Incorporated1989-12-31Not applicableCanada
Methylene Blue Injection USPSolution10 mgIntravenousAlveda Pharmaceuticals Inc2008-08-28Not applicableCanada
Methylene Blue Injection, USPSolution10 mgIntravenousMylan Pharmaceuticals1994-12-31Not applicableCanada
Methylene Blue Injection, USPLiquid1 %IntravenousHospira, Inc.1999-06-232010-03-24Canada
Methylthioninium Chloride ProveblueInjection, solution5 mg/mlIntravenousProvepharm Sas2011-05-06Not applicableEu
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methylene Bleu Liq 1%Liquid1 %OralLaboratoire Atlas Inc1951-12-31Not applicableCanada
Methylene Bleu Liq 2%Liquid2 %OralLaboratoire Atlas Inc1951-12-31Not applicableCanada
Methylene Blue Solution 1%Liquid1 %Oral; TopicalRougier Pharma Division Of Ratiopharm Inc1981-12-312015-10-01Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Blue CollyriumMethylene blue (0.2 mg) + Naphazoline hydrochloride (0.5 mg)LiquidOphthalmicSandoz Canada Incorporated1997-05-13Not applicableCanada
Collyre BleuMethylene blue (0.2 mg) + Naphazoline hydrochloride (0.5 mg)Solution / dropsOphthalmicSabex Inc1991-12-311997-11-26Canada
Collyre Bleu LaiterMethylene blue (0.2 mg) + Naphazoline nitrate (0.5 mg)Solution / dropsOphthalmicBiocodex Sa1986-12-31Not applicableCanada
Eau Resolutive SokerMethylene blue (.1365 mg) + Camphor (.715 mg) + Cupric sulfate (28.925 mg) + Resorcinol (58.565 mg) + Zinc sulfate (88.4 mg)LiquidTopicalProduits Francais Labs Inc.1930-12-311997-05-30Canada
Saprolex TabMethylene blue (10 mg) + Methenamine mandelate (250 mg)TabletOralProduits Francais Labs Inc.1982-12-311997-05-30Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Azuphen MbMethylene blue (10 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (120 mg/1) + Phenyl salicylate (36 mg/1) + Sodium phosphate, monobasic, monohydrate (40.8 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2015-09-282018-01-06Us
Hyolev MbMethylene blue (10.8 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (81 mg/1) + Phenyl salicylate (32.4 mg/1) + Sodium phosphate, monobasic, monohydrate (40.8 mg/1)TabletOralBurel Pharmaceuticals, Llc2015-06-262018-01-06Us
HyophenMethylene blue (10.8 mg/1) + Benzoic Acid (9 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (81.6 mg/1) + Phenyl salicylate (36.2 mg/1)TabletOralStar Pharmaceuticals, Llc2010-09-21Not applicableUs00076 0901 01 nlmimage10 cc15e64f
Indiomin MbMethylene blue (10 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (120 mg/1) + Sodium phosphate, monobasic, monohydrate (40.8 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2015-09-282018-03-15Us
Me NaPhos MB Hyo 1Methylene blue (10.8 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (81.6 mg/1) + Sodium phosphate, monobasic, monohydrate (40.8 mg/1)TabletOralMethod Pharmaceuticals2015-12-01Not applicableUs
Methylene BlueMethylene blue (10 mg/mL)Injection, solutionIntravenousAmerican Regent1990-09-302017-07-20Us
Methylene BlueMethylene blue (10 mg/mL)InjectionIntravenousAkorn2009-04-01Not applicableUs
Methylene BlueMethylene blue (10 mg/mL)Injection, solutionIntravenousGeneral Injectables & Vaccines2010-12-172017-01-20Us
Methylene BlueMethylene blue (10 mg/mL)Injection, solutionIntravenousAmerican Regent1990-09-302017-07-20Us
Methylene BlueMethylene blue (10 mg/mL)Injection, solutionIntravenousGeneral Injectables & Vaccines2010-04-01Not applicableUs
Categories
UNII
8NAP7826UB
CAS number
61-73-4
Weight
Average: 319.85
Monoisotopic: 319.0909965
Chemical Formula
C16H18ClN3S
InChI Key
CXKWCBBOMKCUKX-UHFFFAOYSA-M
InChI
InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1
IUPAC Name
3,7-bis(dimethylamino)-5λ⁴-phenothiazin-5-ylium chloride
SMILES
[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1

Pharmacology

Indication

Methylene blue has several indications in medicine: 1. found to improve the hypotension associated with various clinical states. 2. Antiseptic in urinary tract infections. 3. Improves hypoxia and hyper dynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome. 4. Results in transient and reproducible improvement in blood pressure and cardiac function in septic shock. 5. Investigated for the treatment of Alzheimer's disease. 6. Treatment of ifofosamide induced neurotoxicity.

Pharmacodynamics
Not Available
Mechanism of action
  • Main mechanism of action involves inhibition of nitric oxide synthase and guanylate cyclase.
  • In Alzheimer: a mechanistic study found that methylene blue oxidizes cysteine sulfhydryl groups on tau to keep tau monomeric. One preclinical treatment study in tauopathy mice reported anti-inflammatory or neuroprotective effects mediated by the Nrf2/antioxidant response element (ARE); another reported insoluble tau reduction and a learning and memory benefit when given early.
  • In Methemoglobinemia: Methylene Blue acts by reacting within RBC to form leukomethylene blue, which is a reducing agent of oxidized hemoglobin converting the ferric ion (fe+++) back to its oxygen carrying ferrous state(fe++).
  • As antimalarial agent: Methylene Blue, a specific inhibitor of P.falciparum glutathione reductase has the potential to reverse CQ resistance and it prevents the polymerization of haem into haemozoin similar to 4-amino-quinoline antimalarials.
  • For ifofosamide induced neurotoxicity: Methylene blue acts as an alternative electron acceptor, and reverses the NADH inhibition of hepatic gluconeogenesis while also inhibiting the transformation of chloroethylamine into Chloroacetaldehyde, and also inhibits multiple amine oxidase activities, preventing the formation of Chloroacetaldehyde.
TargetActionsOrganism
AGuanylate cyclase soluble subunit alpha-2
antagonist
Human
ANitric oxide synthase, brain
antagonist
Human
Absorption
Not Available
Volume of distribution

10 mg/kg (in rats).

Protein binding

Methylene blue was reported to bind strongly to rabbit plasma (71–77% of bound drug).

Metabolism

Following distribution into tissues, rapidly reduced to leukomethylene blue (leucomethylthioninium chloride). Metabolism to leucomethylene blue may be less efficient in neonates than in older individuals.

Route of elimination

Excreted in urine and bile. About 75% of an oral dose excreted in urine, primarily as stabilized colorless leukomethylene blue.

Half life

5–6.5 hours (after IV dose).

Clearance

3.0 ± 0.7 L/min.

Toxicity

LD50 = 1180 mg/kg ( Rat ).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Methylene blue.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Methylene blue.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Methylene blue.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Methylene blue.Experimental, Illicit
4-MethoxyamphetamineMethylene blue may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Methylene blue.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Methylene blue can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Methylene blue.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Abediterol.Investigational
AcarboseMethylene blue may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololMethylene blue may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlaproclateAlaproclate may increase the serotonergic activities of Methylene blue.Experimental
AlbiglutideMethylene blue may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methylene blue.Approved, Illicit
AliskirenMethylene blue may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Methylene blue.Approved, Investigational
AlogliptinMethylene blue may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methylene blue.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Methylene blue.Illicit
AlprenololMethylene blue may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Methylene blue.Approved
AluminiumAluminium can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmbrisentanMethylene blue may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineAmineptine may increase the serotonergic activities of Methylene blue.Illicit, Withdrawn
AmiodaroneMethylene blue may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the serotonergic activities of Methylene blue.Approved
AmitriptylinoxideAmitriptylinoxide may increase the serotonergic activities of Methylene blue.Approved, Investigational
AmlodipineMethylene blue may increase the hypotensive activities of Amlodipine.Approved
AmodiaquineThe serum concentration of Methylene blue can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may increase the serotonergic activities of Methylene blue.Approved
AmphetamineAmphetamine may increase the serotonergic activities of Methylene blue.Approved, Illicit, Investigational
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Methylene blue.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Arformoterol.Approved, Investigational
ArotinololMethylene blue may increase the hypotensive activities of Arotinolol.Investigational
ArtemetherThe serum concentration of Methylene blue can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Methylene blue can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Methylene blue can be increased when it is combined with Artemotil.Approved
ArtenimolThe serum concentration of Methylene blue can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Methylene blue can be increased when it is combined with Artesunate.Approved, Investigational
AsenapineMethylene blue may increase the hypotensive activities of Asenapine.Approved
AtenololMethylene blue may increase the hypotensive activities of Atenolol.Approved
AtomoxetineMethylene blue may increase the central neurotoxic activities of Atomoxetine.Approved
AtovaquoneThe serum concentration of Methylene blue can be increased when it is combined with Atovaquone.Approved
AtropineMethylene blue may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Bambuterol.Approved, Investigational
BefunololMethylene blue may increase the hypotensive activities of Befunolol.Experimental
BenazeprilMethylene blue may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideMethylene blue may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Methylene blue.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Methylene blue.Approved, Illicit
BepridilMethylene blue may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Methylene blue.Approved, Investigational
BetaxololMethylene blue may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineMethylene blue may increase the hypotensive activities of Bethanidine.Approved
BevantololMethylene blue may increase the hypotensive activities of Bevantolol.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Methylene blue is combined with Bezafibrate.Approved, Investigational
BezitramideMethylene blue may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
BietaserpineMethylene blue may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostMethylene blue may increase the hypotensive activities of Bimatoprost.Approved, Investigational
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololMethylene blue may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Bitolterol.Withdrawn
BopindololMethylene blue may increase the hypotensive activities of Bopindolol.Approved
BosentanMethylene blue may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Methylene blue may increase the hypotensive activities of BQ-123.Investigational
BretyliumMethylene blue may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Methylene blue.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Brimonidine.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Methylene blue.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Methylene blue.Approved, Investigational
BucindololMethylene blue may increase the hypotensive activities of Bucindolol.Investigational
BufuralolMethylene blue may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupranololMethylene blue may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methylene blue.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Methylene blue is combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Methylene blue.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methylene blue.Approved, Illicit, Vet Approved
ButriptylineButriptyline may increase the serotonergic activities of Methylene blue.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Methylene blue.Approved
CadralazineMethylene blue may increase the hypotensive activities of Cadralazine.Experimental
CafedrineMethylene blue may increase the hypotensive activities of Cafedrine.Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinMethylene blue may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanMethylene blue may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilMethylene blue may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilMethylene blue may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilMethylene blue may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methylene blue.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methylene blue.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Methylene blue.Approved, Investigational
CaroxazoneCaroxazone may increase the serotonergic activities of Methylene blue.Withdrawn
CarteololMethylene blue may increase the hypotensive activities of Carteolol.Approved
CarvedilolMethylene blue may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololMethylene blue may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe serum concentration of Methylene blue can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideMethylene blue may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Methylene blue.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Methylene blue can be increased when it is combined with Chlorproguanil.Investigational
ChlorpropamideMethylene blue may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneMethylene blue may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineMethylene blue may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilMethylene blue may increase the hypotensive activities of Cilazapril.Approved
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Methylene blue.Approved, Investigational
CirazolineMethylene blue may increase the hypertensive activities of Cirazoline.Experimental
CitalopramCitalopram may increase the serotonergic activities of Methylene blue.Approved
ClemastineMethylene blue may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineClomipramine may increase the serotonergic activities of Methylene blue.Approved, Investigational, Vet Approved
ClonidineMethylene blue may increase the hypertensive activities of Clonidine.Approved
CloranololMethylene blue may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methylene blue.Approved, Illicit
CryptenamineMethylene blue may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Methylene blue.Approved
Cycloguanil embonateThe serum concentration of Methylene blue can be increased when it is combined with Cycloguanil embonate.Experimental
CyclopenthiazideMethylene blue may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideMethylene blue may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineMethylene blue may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinMethylene blue may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineDapoxetine may increase the serotonergic activities of Methylene blue.Investigational
DapsoneThe serum concentration of Methylene blue can be increased when it is combined with Dapsone.Approved, Investigational
DebrisoquinMethylene blue may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilMethylene blue may increase the hypotensive activities of Delapril.Investigational
DeserpidineMethylene blue may increase the hypotensive activities of Deserpidine.Approved
DesipramineDesipramine may increase the serotonergic activities of Methylene blue.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Methylene blue.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Deutetrabenazine.Approved, Investigational
DexmethylphenidateMethylene blue may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Methylene blue.Approved, Illicit
DextromethorphanMethylene blue may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methylene blue.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methylene blue.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methylene blue.Approved, Investigational
DiazoxideMethylene blue may increase the hypotensive activities of Diazoxide.Approved
DibenzepinDibenzepin may increase the serotonergic activities of Methylene blue.Experimental
DiethylnorspermineMethylene blue may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionMethylene blue may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineMethylene blue may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methylene blue.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Methylene blue.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methylene blue.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methylene blue.Experimental, Illicit
DiltiazemMethylene blue may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimetacrineDimetacrine may increase the serotonergic activities of Methylene blue.Approved, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methylene blue.Approved, Illicit
DipivefrinMethylene blue may increase the hypertensive activities of Dipivefrin.Approved
DisopyramideMethylene blue may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Methylene blue is combined with Disulfiram.Approved
DobutamineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Methylene blue is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideMethylene blue may increase the hypotensive activities of Dorzolamide.Approved
DosulepinDosulepin may increase the serotonergic activities of Methylene blue.Approved
DoxapramMethylene blue may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinMethylene blue may increase the hypotensive activities of Doxazosin.Approved
DoxepinDoxepin may increase the serotonergic activities of Methylene blue.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Doxofylline.Approved, Investigational
DoxycyclineThe serum concentration of Methylene blue can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineMethylene blue may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Methylene blue.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methylene blue.Experimental, Illicit
DroxidopaMethylene blue may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideMethylene blue may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Methylene blue.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methylene blue.Experimental, Illicit
EfonidipineMethylene blue may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Methylene blue.Approved, Investigational
EmpagliflozinMethylene blue may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilMethylene blue may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatMethylene blue may increase the hypotensive activities of Enalaprilat.Approved
EndralazineMethylene blue may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Methylene blue.Approved, Investigational
EpanololMethylene blue may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Methylene blue is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineMethylene blue may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolMethylene blue may increase the hypotensive activities of Epoprostenol.Approved
EprosartanMethylene blue may increase the hypotensive activities of Eprosartan.Approved
ErgonovineMethylene blue may increase the hypertensive activities of Ergonovine.Approved
ErgotamineMethylene blue may increase the hypertensive activities of Ergotamine.Approved
EsatenololMethylene blue may increase the hypotensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the serotonergic activities of Methylene blue.Approved, Investigational
EsmololMethylene blue may increase the hypotensive activities of Esmolol.Approved
EtafedrineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methylene blue.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methylene blue.Approved, Illicit
EtoperidoneEtoperidone may increase the serotonergic activities of Methylene blue.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methylene blue.Illicit, Vet Approved
ExenatideMethylene blue may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineMethylene blue may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamMethylene blue may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methylene blue.Approved, Illicit, Investigational, Vet Approved
Ferulic acidMethylene blue may increase the hypotensive activities of Ferulic acid.Experimental
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Methylene blue.Approved, Investigational
FluoxetineFluoxetine may increase the serotonergic activities of Methylene blue.Approved, Vet Approved
FluvoxamineFluvoxamine may increase the serotonergic activities of Methylene blue.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Formoterol.Approved, Investigational
FosinoprilMethylene blue may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Methylene blue.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Methylene blue.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Methylene blue.Experimental
GliclazideMethylene blue may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMethylene blue may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMethylene blue may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideMethylene blue may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzMethylene blue may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelMethylene blue may increase the hypotensive activities of Guanadrel.Approved
GuanazodineMethylene blue may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineMethylene blue may increase the hypotensive activities of Guanethidine.Approved
GuanfacineMethylene blue may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorMethylene blue may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMethylene blue may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMethylene blue may increase the hypotensive activities of Guanoxan.Experimental
HalofantrineThe serum concentration of Methylene blue can be increased when it is combined with Halofantrine.Approved
HarmalineHarmaline may increase the serotonergic activities of Methylene blue.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methylene blue.Approved, Illicit, Investigational
HexamethoniumMethylene blue may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineHydracarbazine may increase the serotonergic activities of Methylene blue.Experimental
HydralazineMethylene blue may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideMethylene blue may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methylene blue.Approved, Illicit
HydroflumethiazideMethylene blue may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylene blue.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Methylene blue.Approved
HydroxychloroquineThe serum concentration of Methylene blue can be increased when it is combined with Hydroxychloroquine.Approved
ImidaprilMethylene blue may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may increase the serotonergic activities of Methylene blue.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Indacaterol.Approved
IndalpineIndalpine may increase the serotonergic activities of Methylene blue.Investigational, Withdrawn
IndapamideMethylene blue may increase the hypotensive activities of Indapamide.Approved
IndenololMethylene blue may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminMethylene blue may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartMethylene blue may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirMethylene blue may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineMethylene blue may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineMethylene blue may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanMethylene blue may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproMethylene blue may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Methylene blue.Approved
IprindoleIprindole may increase the serotonergic activities of Methylene blue.Experimental
IproclozideIproclozide may increase the serotonergic activities of Methylene blue.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Methylene blue.Withdrawn
IrbesartanMethylene blue may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Methylene blue.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Methylene blue is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Isoprenaline.Approved, Investigational
IsradipineMethylene blue may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinMethylene blue may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methylene blue.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Methylene blue.Approved, Nutraceutical, Withdrawn
LabetalolMethylene blue may increase the hypotensive activities of Labetalol.Approved
LacidipineMethylene blue may increase the hypotensive activities of Lacidipine.Approved, Investigational
LandiololMethylene blue may increase the hypotensive activities of Landiolol.Investigational
LatanoprostMethylene blue may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineMethylene blue may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobetaxololMethylene blue may increase the hypotensive activities of Levobetaxolol.Approved, Investigational
LevobunololMethylene blue may increase the hypotensive activities of Levobunolol.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Methylene blue.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methylene blue.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Methylene blue.Approved, Investigational
LevonordefrinMethylene blue may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methylene blue.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Methylene blue is combined with Linezolid.Approved, Investigational
LinsidomineMethylene blue may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideMethylene blue may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Methylene blue.Approved, Investigational
LisinoprilMethylene blue may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Methylene blue.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Methylene blue is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Methylene blue.Illicit
LofepramineLofepramine may increase the serotonergic activities of Methylene blue.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Methylene blue.Approved, Investigational
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Methylene blue.Approved
LosartanMethylene blue may increase the hypotensive activities of Losartan.Approved
LumefantrineThe serum concentration of Methylene blue can be increased when it is combined with Lumefantrine.Approved
MacitentanMethylene blue may increase the hypotensive activities of Macitentan.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineMethylene blue may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the serotonergic activities of Methylene blue.Approved, Investigational
MebanazineMebanazine may increase the serotonergic activities of Methylene blue.Withdrawn
MecamylamineMethylene blue may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminMethylene blue may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MefloquineThe serum concentration of Methylene blue can be increased when it is combined with Mefloquine.Approved, Investigational
MelitracenMelitracen may increase the serotonergic activities of Methylene blue.Experimental, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Methylene blue.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Methylene blue.Approved
MepindololMethylene blue may increase the hypotensive activities of Mepindolol.Experimental
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Methylene blue.Experimental
MequitazineMethylene blue may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolMethylene blue may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminMethylene blue may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methylene blue is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methylene blue.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Methylene blue.Approved, Illicit
MethoserpidineMethylene blue may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineMethylene blue may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Methylene blue.Experimental
MethyldopaThe risk or severity of hypertension can be increased when Methylene blue is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Methylene blue.Experimental
MethylphenidateMethylene blue may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethysergideThe metabolism of Methysergide can be decreased when combined with Methylene blue.Approved
MetipranololMethylene blue may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMethylene blue may increase the hypotensive activities of Metolazone.Approved
MetoprololMethylene blue may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineMethylene blue may increase the hypotensive activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Methylene blue is combined with Mianserin.Approved, Investigational
MibefradilMethylene blue may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineMethylene blue may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Methylene blue.Experimental, Illicit, Investigational
MifepristoneMethylene blue may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolMethylene blue may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the serotonergic activities of Methylene blue.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Methylene blue.Approved
MinoxidilMethylene blue may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineMirtazapine may increase the serotonergic activities of Methylene blue.Approved
MizoribineThe serum concentration of Methylene blue can be increased when it is combined with Mizoribine.Investigational
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Methylene blue.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Methylene blue.Approved, Investigational
MoexiprilMethylene blue may increase the hypotensive activities of Moexipril.Approved
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Methylene blue.Approved, Investigational
MoxonidineMethylene blue may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineMethylene blue may increase the hypotensive activities of Muzolimine.Experimental
NadololMethylene blue may increase the hypotensive activities of Nadolol.Approved
NaftopidilMethylene blue may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methylene blue.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Methylene blue.Investigational
NaphazolineMethylene blue may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Methylene blue.Approved, Investigational
NateglinideMethylene blue may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololMethylene blue may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the serotonergic activities of Methylene blue.Approved, Withdrawn
NialamideNialamide may increase the serotonergic activities of Methylene blue.Withdrawn
NicardipineMethylene blue may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicomorphineMethylene blue may increase the hypotensive activities of Nicomorphine.Experimental
NicorandilMethylene blue may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineMethylene blue may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMethylene blue may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineMethylene blue may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineMethylene blue may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineMethylene blue may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideMethylene blue may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorepinephrineMethylene blue may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Methylene blue.Approved, Illicit
NortriptylineNortriptyline may increase the serotonergic activities of Methylene blue.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Methylene blue.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Olanzapine.Approved, Investigational
OlmesartanMethylene blue may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Olodaterol.Approved
OmapatrilatMethylene blue may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolOpipramol may increase the serotonergic activities of Methylene blue.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Methylene blue.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Orciprenaline.Approved
OxprenololMethylene blue may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Methylene blue is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineMethylene blue may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methylene blue.Approved, Investigational, Vet Approved
PargylinePargyline may increase the serotonergic activities of Methylene blue.Approved
ParoxetineParoxetine may increase the serotonergic activities of Methylene blue.Approved, Investigational
PenbutololMethylene blue may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineMethylene blue may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methylene blue.Approved, Vet Approved
PentoliniumMethylene blue may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Methylene blue.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilMethylene blue may increase the hypotensive activities of Perindopril.Approved
PethidineMethylene blue may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Methylene blue is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Methylene blue.Experimental
PhendimetrazineMethylene blue may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the serotonergic activities of Methylene blue.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Methylene blue.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Methylene blue.Experimental
PhenoxybenzamineMethylene blue may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Methylene blue.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Methylene blue.Approved, Illicit
PhentolamineMethylene blue may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineMethylene blue may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Methylene blue.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Methylene blue.Investigational
PinacidilMethylene blue may increase the hypotensive activities of Pinacidil.Approved
PindololMethylene blue may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneMethylene blue may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PiperaquineThe serum concentration of Methylene blue can be increased when it is combined with Piperaquine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Methylene blue.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Methylene blue.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Methylene blue.Withdrawn
PizotifenMethylene blue may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorMethylene blue may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideMethylene blue may increase the hypotensive activities of Polythiazide.Approved
PractololMethylene blue may increase the hypotensive activities of Practolol.Approved
PramlintideMethylene blue may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinMethylene blue may increase the hypotensive activities of Prazosin.Approved
PrimaquineThe serum concentration of Methylene blue can be increased when it is combined with Primaquine.Approved
ProcaineProcaine may increase the serotonergic activities of Methylene blue.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Methylene blue.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Procaterol.Approved, Investigational
ProguanilThe serum concentration of Methylene blue can be increased when it is combined with Proguanil.Approved
PropafenoneMethylene blue may increase the hypotensive activities of Propafenone.Approved
PropranololMethylene blue may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Protokylol.Approved, Vet Approved
ProtriptylineProtriptyline may increase the serotonergic activities of Methylene blue.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Methylene blue.Approved
PyrimethamineThe serum concentration of Methylene blue can be increased when it is combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyronaridineThe serum concentration of Methylene blue can be increased when it is combined with Pyronaridine.Investigational
QuinacrineThe serum concentration of Methylene blue can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilMethylene blue may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe serum concentration of Methylene blue can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Methylene blue can be increased when it is combined with Quinine.Approved
RacepinephrineMethylene blue may increase the hypertensive activities of Racepinephrine.Approved
RadicicolThe serum concentration of Methylene blue can be increased when it is combined with Radicicol.Experimental
RamiprilMethylene blue may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the serotonergic activities of Methylene blue.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methylene blue.Approved
RemikirenMethylene blue may increase the hypotensive activities of Remikiren.Approved
RepaglinideMethylene blue may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineMethylene blue may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Reserpine.Approved, Investigational
RilmenidineMethylene blue may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatMethylene blue may increase the hypotensive activities of Riociguat.Approved
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Methylene blue.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Ritodrine.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Methylene blue.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Methylene blue.Approved, Investigational
RosiglitazoneMethylene blue may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Methylene blue.Approved
SafrazineSafrazine may increase the serotonergic activities of Methylene blue.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Salmeterol.Approved
SaprisartanMethylene blue may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinMethylene blue may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the serotonergic activities of Methylene blue.Approved, Investigational, Vet Approved
SelexipagMethylene blue may increase the hypotensive activities of Selexipag.Approved
SertralineSertraline may increase the serotonergic activities of Methylene blue.Approved
SinefunginThe serum concentration of Methylene blue can be increased when it is combined with Sinefungin.Experimental
SitagliptinMethylene blue may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanMethylene blue may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolMethylene blue may increase the hypotensive activities of Sotalol.Approved
SpiraprilMethylene blue may increase the hypotensive activities of Spirapril.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methylene blue.Approved, Investigational
SulfadiazineMethylene blue may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfadoxineThe serum concentration of Methylene blue can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfamethoxazoleMethylene blue may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfametopyrazineThe serum concentration of Methylene blue can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazoleMethylene blue may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Methylene blue.Approved, Investigational
SunitinibMethylene blue may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TafenoquineThe serum concentration of Methylene blue can be increased when it is combined with Tafenoquine.Investigational
TalinololMethylene blue may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methylene blue.Approved
TelmisartanMethylene blue may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilMethylene blue may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Terbutaline.Approved
TerlipressinMethylene blue may increase the hypotensive activities of Terlipressin.Approved, Investigational
TertatololMethylene blue may increase the hypotensive activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Tetrabenazine.Approved, Investigational
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Methylene blue.Investigational
TetrahydropalmatineMethylene blue may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineMethylene blue may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineMethylene blue may increase the hypotensive activities of Theodrenaline.Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Methylene blue is combined with Thiopental.Approved, Vet Approved
TianeptineTianeptine may increase the serotonergic activities of Methylene blue.Approved, Investigational
TiboloneMethylene blue may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenMethylene blue may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Methylene blue.Experimental
TimololMethylene blue may increase the hypotensive activities of Timolol.Approved
TolazamideMethylene blue may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineMethylene blue may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideMethylene blue may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methylene blue.Approved, Withdrawn
TolonidineMethylene blue may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the serotonergic activities of Methylene blue.Approved
TorasemideMethylene blue may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Methylene blue.Approved, Investigational
TrandolaprilMethylene blue may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the serotonergic activities of Methylene blue.Approved, Investigational
TravoprostMethylene blue may increase the hypotensive activities of Travoprost.Approved
TrazodoneTrazodone may increase the serotonergic activities of Methylene blue.Approved, Investigational
TreprostinilMethylene blue may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideMethylene blue may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinMethylene blue may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanMethylene blue may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimethoprimThe serum concentration of Methylene blue can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the serotonergic activities of Methylene blue.Approved
TromethamineTromethamine can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UnoprostoneMethylene blue may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilMethylene blue may increase the hypotensive activities of Urapidil.Investigational
ValsartanMethylene blue may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineVenlafaxine may increase the serotonergic activities of Methylene blue.Approved
VilanterolThe risk or severity of adverse effects can be increased when Methylene blue is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Methylene blue.Approved
VincamineMethylene blue may increase the hypotensive activities of Vincamine.Experimental
VinpocetineMethylene blue may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Methylene blue.Approved, Investigational
XipamideMethylene blue may increase the hypotensive activities of Xipamide.Experimental
XylometazolineMethylene blue may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZimelidineZimelidine may increase the serotonergic activities of Methylene blue.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Methylene blue.Approved
ZofenoprilMethylene blue may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Methylene blue.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Ozal E, Kuralay E, Yildirim V, Kilic S, Bolcal C, Kucukarslan N, Gunay C, Demirkilic U, Tatar H: Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg. 2005 May;79(5):1615-9. [PubMed:15854942]
  2. Tuman KJ, McCarthy RJ, O'Connor CJ, Holm WE, Ivankovich AD: Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg. 1995 Mar;80(3):473-9. [PubMed:7864410]
  3. Meissner PE, Mandi G, Coulibaly B, Witte S, Tapsoba T, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Walter-Sack I, Mikus G, Burhenne J, Riedel KD, Schirmer RH, Kouyate B, Muller O: Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J. 2006 Oct 8;5:84. [PubMed:17026773]
  4. Boylston M, Beer D: Methemoglobinemia: a case study. Crit Care Nurse. 2002 Aug;22(4):50-5. [PubMed:12166056]
  5. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000 Jan;82(2):291-4. [PubMed:10646879]
  6. product info [Link]
  7. Article\ [Link]
  8. article [Link]
  9. Drug info [Link]
  10. Monograph [Link]
  11. msds [Link]
External Links
KEGG Compound
C00220
PubChem Compound
6099
PubChem Substance
310265144
ChemSpider
5874
ChEBI
6872
ChEMBL
CHEMBL405110
Wikipedia
Methylthioninium_chloride
ATC Codes
V03AB17 — Methylthioninium chlorideV04CG05 — Methylthioninium chloride
AHFS Codes
  • 92:12.00 — Antidotes
  • 36:36.00 — Gastric Function
  • 92:00.00 — Miscellaneous Therapeutic Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentDiseases of Oral Cavity Salivary Glands and Jaws1
1CompletedTreatmentCongenital methaemoglobinaemia / Methaemoglobinaemia1
1CompletedTreatmentG6PD Deficient / G6PD Normal / Healthy Volunteers1
1RecruitingTreatmentAbscesses1
1TerminatedTreatmentSepsis1
2Active Not RecruitingTreatmentAD / Aging / Alzheimer's Disease (AD) / MCI / Mild Cognitive Impairment (MCI)1
2CompletedNot AvailableBrain Activity1
2CompletedDiagnosticCancer, Breast1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentDementia, Alzheimer Type1
2CompletedTreatmentMalaria caused by Plasmodium falciparum1
2CompletedTreatmentPlasmodium Infections2
2Not Yet RecruitingTreatmentArterial Hypotension / Cardiac Valve Disease / Coronary Artery Disease / Vasoplegia1
2RecruitingTreatmentPeriradicular Disease1
2TerminatedSupportive CareLymphedema of the extremities / Recurrent Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer1
3CompletedTreatmentBipolar Disorder (BD)1
3Not Yet RecruitingTreatmentDysuria1
3RecruitingDiagnosticLiver Diseases1
3RecruitingTreatmentRefractory Shock / Shock, Septic1
3RecruitingTreatmentSevere Sepsis / Shock, Septic1
4CompletedSupportive CareLiver Cirrhosis / Refractory Shock / Shock, Septic / Vasoplegia1
4Not Yet RecruitingSupportive CareSepsis1
4Not Yet RecruitingTreatmentAcquired Methaemoglobinaemia1
4TerminatedPreventionSecretion Removal Above ETT Cuff1
Not AvailableCompletedNot AvailableHyperparathyroidism1
Not AvailableCompletedBasic ScienceChronic Periodontitis1
Not AvailableCompletedDiagnosticMelanoma / Sentinel Node1
Not AvailableCompletedPreventionRespiratory Aspiration1
Not AvailableCompletedTreatmentCancer, Breast / Sentinel Lymph Node1
Not AvailableCompletedTreatmentInfiltrative Breast Cancer1
Not AvailableCompletedTreatmentLaparoscopy / Methylene Blue / Tubal Patency1
Not AvailableCompletedTreatmentPain, Neuropathic1
Not AvailableEnrolling by InvitationDiagnosticEarly Gastric Cancer / Malignant Neoplasm of Stomach / Sentinel Lymph Node1
Not AvailableEnrolling by InvitationTreatmentCancer, Breast / Sentinel Lymph Node1
Not AvailableRecruitingNot AvailableMethaemoglobinaemia / Methemoglobinemia, Acquired1
Not AvailableRecruitingOtherBile Duct Injury1
Not AvailableRecruitingPreventionJaundice, Obstructive1
Not AvailableTerminatedDiagnosticAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Stage I Cervical Cancer1
Not AvailableWithdrawnTreatmentSepsis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidOphthalmic
Solution / dropsOphthalmic
LiquidTopical
LiquidOral1 %
LiquidOral2 %
InjectionIntravenous10 mg/mL
Injection, solutionIntravenous10 mg/mL
LiquidIntramuscular; Intravenous10 mg
LiquidIntravenous1 %
SolutionIntravenous10 mg
LiquidIntravenous10 mg
SolutionParenteral10 mg
LiquidOral; Topical1 %
Injection, solutionIntravenous5 mg/ml
InjectionIntravenous5 mg/mL
CapsuleOral
Tablet, coatedOral
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)100 to 110 °C (with decomposition)Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0296 mg/mLALOGPS
logP3.61ALOGPS
logP2.61ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)2.44ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area19.37 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity86.98 m3·mol-1ChemAxon
Polarizability33.1 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Not Available
Direct Parent
Benzothiazines
Alternative Parents
Dialkylarylamines / Benzenoids / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organic chloride salts / Hydrocarbon derivatives
Substituents
Benzothiazine / Dialkylarylamine / Tertiary aliphatic/aromatic amine / Benzenoid / Heteroaromatic compound / Tertiary amine / Azacycle / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic chloride salt (CHEBI:6872)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Heme binding
Specific Function
Has guanylyl cyclase on binding to the beta-1 subunit.Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits.
Gene Name
GUCY1A2
Uniprot ID
P33402
Uniprot Name
Guanylate cyclase soluble subunit alpha-2
Molecular Weight
81749.185 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. P...
Gene Name
NOS1
Uniprot ID
P29475
Uniprot Name
Nitric oxide synthase, brain
Molecular Weight
160969.095 Da

Drug created on October 23, 2015 14:18 / Updated on July 16, 2018 21:27